SHELTON,
Conn., Feb. 21, 2024 /PRNewswire/
-- Intensity Therapeutics, Inc. (Nasdaq: INTS), a
late-stage clinical biotechnology company focused on the discovery
and development of proprietary, novel immune-based intratumoral
cancer therapies designed to kill tumors and increase immune system
recognition of cancers, today announced that Lewis H. Bender, President and Chief Executive
Officer, will present a company overview at the 2024 BIO CEO &
Investor Conference on Monday, February 26,
2024, at the New York Marriott Marquis at 11:45am ET in the Uris Room.
Mr. Bender will also host in-person one-on-one meetings during
the event. For more information about the 2024 BIO CEO &
Investor Conference, please visit https://bcic.bio.org/
About Intensity Therapeutics
Intensity Therapeutics is
a late-stage clinical biotechnology company that applies novel
engineered chemistry to turn "cold" tumors "hot" by enabling its
aqueous cytotoxic-containing drug product, INT230-6, to mix and
saturate the dense, high-fat pressurized environment of the tumor.
As a result of the saturation, Intensity's clinical trials have
demonstrated the ability of INT230-6 to kill tumors and elicit an
adaptive immune response within days of injection, representing a
novel approach to cancer cell death that holds the potential to
shift the treatment paradigm and turn many deadly cancers into
chronic diseases. INT230-6 has completed enrollment of over 200
patients in a phase 1/2 dose escalation trial (NCT03058289) and
phase 2 randomized control clinical trial in breast cancer (the
INVINCIBLE 2 study) (NCT04781725). The Company is initiating
a phase 3 trial in soft tissue sarcoma (the INVINCIBLE 3 study)
(NCT06263231), testing INT230-6 as second or third line monotherapy
compared to the standard of care with overall survival as an
endpoint. The Company is also planning a phase 2/3 program in
presurgical triple negative breast cancer testing INT230-6 in
combination with standard of care compared to standard of care
alone. For more information about the Company, including
publications, papers and posters about its novel approach to cancer
therapeutics, visit www.intensitytherapeutics.com.
Forward-Looking Statements
Certain statements in this
press release may constitute "forward-looking statements" within
the meaning of the United States Private Securities Litigation
Reform Act of 1995, as amended to date. These statements include,
but are not limited to, statements relating to the expected future
plans, development activities, projected milestones, business
activities or results. We have based these forward-looking
statements on our current expectations and projections about future
events, nevertheless, actual results or events could differ
materially from the plans, intentions and expectations disclosed
in, or implied by, the forward-looking statements we make. These
risks and uncertainties, many of which are beyond our control,
include: the risk that the anticipated milestones may be delayed or
not occur or be changed, as well as other risks described in the
section entitled "Risk Factors" in the Company's SEC filings, which
can be obtained on the SEC website at www.sec.gov. Readers are
cautioned not to place undue reliance on the forward-looking
statements, which speak only as of the date on which they are made
and reflect management's current estimates, projections,
expectations and beliefs. The Company does not plan to update any
such forward-looking statements and expressly disclaims any duty to
update the information contained in this press release except as
required by law.
Investor Relations Contact:
Justin Kulik
CORE IR
ir@intensitytherapeutics.com
(516) 222-2560
Media Contact:
CoreIR
pr@coreir.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/intensity-therapeutics-to-present-at-the-2024-bio-ceo--investor-conference-302066806.html
SOURCE Intensity Therapeutics Inc.
